Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idetrexed and Olaparib in Ovarian Cancer
NCT06976892Phase 1Recruiting
- Sponsor
- The Institute of Cancer Research
- Start
- Aug 2025
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of CT900 in High-Grade Serous Ovarian Carcinoma (HGSOC) (2 arms), sponsored by The Institute of Cancer Research. Primary endpoints: Recommended Phase II Dose and Schedule, Safety and Toxicity Profile and 1 more. Started Aug 2025; status: recruiting.
02
Drugs
CT900
03
Conditions
High-Grade Serous Ovarian Carcinoma (HGSOC)
Beyond the preview
Go deeper on NCT06976892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06976892.